Stock 301230 PHARMARESOURCES (SHANGHAI) CO., LTD.
Add to a list
To use this feature you must be a member
Log inSign up

Financials PharmaResources (Shanghai) Co., Ltd.

Equities

301230

CNE1000065Q9

Biotechnology & Medical Research

End-of-day quote Shenzhen S.E.
Other stock markets
 06:00:00 2024-05-26 pm EDT 		5-day change 1st Jan Change
34.4 CNY +1.71% Intraday chart for PharmaResources (Shanghai) Co., Ltd. -4.31% -3.91%
Apr. 25 PharmaResources Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2024 CI
Apr. 24 PharmaResources Co., Ltd. Proposes Final Cash Dividend for the Year 2023 CI

Valuation

Fiscal Period: December 2022 2023 2024 2025
Capitalization 1 4,107 3,853 3,681 -
Enterprise Value (EV) 1 4,107 3,853 3,681 3,681
P/E ratio 48.6 x 102 x 25.1 x 18.7 x
Yield - - - -
Capitalization / Revenue 8.58 x 7.87 x 4.32 x 3.29 x
EV / Revenue 8.58 x 7.87 x 4.32 x 3.29 x
EV / EBITDA 41.7 x 54.1 x 21.2 x 15.5 x
EV / FCF - - - -
FCF Yield - - - -
Price to Book 3.69 x 3.45 x 2.79 x 2.47 x
Nbr of stocks (in thousands) 107,623 107,623 106,993 -
Reference price 2 38.16 35.80 33.82 33.82
Announcement Date 4/21/23 4/23/24 - -
1CNY in Million2CNY
Estimates

Income Statement Evolution (Annual data)

Fiscal Period: December 2021 2022 2023 2024 2025
Net sales 1 - 478.9 489.7 852 1,119
EBITDA 1 - 98.45 71.21 174 238
EBIT 1 - 72.85 37.44 165 221
Operating Margin - 15.21% 7.65% 19.37% 19.75%
Earnings before Tax (EBT) 1 - 72.92 36.76 165 221
Net income 1 73.58 67.18 37.62 146 195
Net margin - 14.03% 7.68% 17.14% 17.43%
EPS 2 0.9143 0.7857 0.3500 1.350 1.810
Free Cash Flow - - - - -
FCF margin - - - - -
FCF Conversion (EBITDA) - - - - -
FCF Conversion (Net income) - - - - -
Dividend per Share - - - - -
Announcement Date 4/14/22 4/21/23 4/23/24 - -
1CNY in Million2CNY
Estimates

Income Statement Evolution (Quarterly data)

Fiscal Period: December 2024 Q1
Net sales 1 130.7
EBITDA -
EBIT -
Operating Margin -
Earnings before Tax (EBT) -
Net income 1 3.668
Net margin 2.81%
EPS -
Dividend per Share -
Announcement Date 4/25/24
1CNY in Million
Estimates

Balance Sheet Analysis

Fiscal Period: December 2021 2022 2023 2024 2025
Net Debt - - - - -
Net Cash position - - - - -
Leverage (Debt/EBITDA) - - - - -
Free Cash Flow - - - - -
ROE (net income / shareholders' equity) - 13.4% 3.39% 11.2% 13.2%
ROA (Net income/ Total Assets) - - - 9.3% 11.1%
Assets 1 - - - 1,570 1,757
Book Value Per Share 2 - 10.30 10.40 12.10 13.70
Cash Flow per Share - - - - -
Capex 1 - 124 248 90 90
Capex / Sales - 25.89% 50.69% 10.56% 8.04%
Announcement Date 4/14/22 4/21/23 4/23/24 - -
1CNY in Million2CNY
Estimates

EPS & Dividend

Year-on-year evolution of the PER

Change in Enterprise Value/EBITDA

Ratings for PharmaResources (Shanghai) Co., Ltd.

Trading Rating
Investor Rating
ESG Refinitiv
More Ratings

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
1
Last Close Price
34.4
Average target price
-
Consensus

EPS Revisions

Estimates Revisions

Annual profits - Rate of surprise

Company calendar

Sector Other Biotechnology & Medical Research

1st Jan change Capi.
PHARMARESOURCES (SHANGHAI) CO., LTD. Stock PharmaResources (Shanghai) Co., Ltd.
-3.91% 500M
MODERNA, INC. Stock Moderna, Inc.
+67.53% 63.85B
IQVIA HOLDINGS INC. Stock Iqvia Holdings Inc.
-0.77% 41.83B
LONZA GROUP AG Stock Lonza Group AG
+44.98% 40.65B
CELLTRION, INC. Stock Celltrion, Inc.
-10.87% 27.12B
ICON PUBLIC LIMITED COMPANY Stock ICON Public Limited Company
+13.30% 26.52B
ALNYLAM PHARMACEUTICALS, INC. Stock Alnylam Pharmaceuticals, Inc.
-22.79% 18.69B
BIO-TECHNE CORPORATION Stock Bio-Techne Corporation
+4.70% 12.73B
UNITED THERAPEUTICS CORPORATION Stock United Therapeutics Corporation
+24.10% 12.11B
MEDPACE HOLDINGS, INC. Stock Medpace Holdings, Inc.
+27.41% 12.07B
Other Biotechnology & Medical Research
  1. Stock Market
  2. Equities
  3. 301230 Stock
  4. Financials PharmaResources (Shanghai) Co., Ltd.